A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (Stereotactic ablative body radiotherapy) with AteZolizumab in patients with advanced Triple nEgative breast Cancer
Primary Sponsor
Victorian Comprehensive Cancer Centre (VCCC)
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG)
Accrual Target
32
Final Accrual
32
Closing Date of Accrual
22 November 2022
Trial Chairperson
Dr Steven David, Peter MacCallum Cancer Centre, VIC
Related Post
5 December, 2024
Extended follow-up of TROG 99.03 lymphoma trial published
5 December 2024: Study shows huge improvement in progression-free
28 November, 2024
Meet TROG President: A/Prof Puma Sandaresan
28 November 2024: In this Q&A, TROG President A/Prof
